Lv21
110 积分 2023-04-11 加入
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study
3小时前
已完结
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study
1个月前
已完结
Population Pharmacokinetics and Pharmacodynamics of Pegozafermin in Patients with Nonalcoholic Steatohepatitis
1个月前
已完结
Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis
1个月前
已完结
Efficacy and safety of FGF21 analogues for metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis
1个月前
已关闭
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
1个月前
已完结
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study
1个月前
已完结
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
1个月前
已完结
The art and science of drug titration
2个月前
已完结
Smoking and tardive dyskinesia in male patients with chronic schizophrenia
3个月前
已完结
皖公网安备34019202002308
